The FDA approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies. In TRANSCEND FL, the CAR T therapy showed a 95.5% overall response rate and 62.1% complete response rate.
The FDA cleared neuromodulation devices from Epineuron, Aneuvo and Encora Therapeutics. The products address peripheral nerve surgery, spinal cord injury neurorehabilitation and essential tremor.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07049003 |
Deep Brain Stimulation of the Deep Cerebellar Nuclei for Refractory Tremor |
RECRUITING | PHASE1 |
| NCT05413291 |
Natural History Protocol for Movement Disorders |
RECRUITING |
